Product Name
MDMG-935P, ≥98% (HPLC), powder, GO inhibitor
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear (warmed)
storage temp.
2-8°C
Application
MDMG-935P may be used for evaluating the expression of fatty acid oxidation (FAO) genes and inflammatory/fibrotic markers, and for assessing liver steatosis.
Biochem/physiol Actions
MDMG-935P is a potent dual, noncompetitive inhibitor of glycolateoxidase (GO) and lactate dehydrogenase A (LDHA), targeting catalytic bindingsites with an IC50 of 9 µM for hLDHA and demonstrating robust in vitro oxalatereduction. It selectively modulates key pathways involved in oxalateoverproduction and upregulates fatty acid oxidation genes, such as CPT1α,showing significant efficacy in reducing liver triglycerides, oxalate levels,and hepatic fibrosis in MASH mouse models at an oral dose of 10 mg/kg. Invitro, Agxt1−/− mouse hepatocytes are employed to model primary hyperoxaluria,and HEK-293 cells are used to assess cytotoxicity. With its favorable metabolicstability, minimal toxicity, anti-fibrotic properties, oral bioavailability, and enhanced efficacy, MDMG-935P is an invaluable tool for investigatinghyperoxaluria and metabolic liver diseases.
Storage Class
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Maria Dolores Moya-Garzon et al.
European journal of medicinal chemistry, 237, 114396-114396 (2022-05-03)
The synthesis and biological evaluation of double glycolate oxidase/lactate dehydrogenase inhibitors containing a salicylic acid moiety is described. The target compounds are obtained in an easily scalable two-step synthetic procedure. These compounds showed low micromolar IC50 values against the two
Sandeep Das et al.
Nature metabolism, 6(10), 1939-1962 (2024-09-28)
The incidence of metabolic dysfunction-associated steatohepatitis (MASH) is on the rise, and with limited pharmacological therapy available, identification of new metabolic targets is urgently needed. Oxalate is a terminal metabolite produced from glyoxylate by hepatic lactate dehydrogenase (LDHA). The liver-specific
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service